{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:31:17Z","timestamp":1761647477809},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.2515\/therapie:2004020","type":"journal-article","created":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T15:42:11Z","timestamp":1173886931000},"page":"97-103","source":"Crossref","is-referenced-by-count":8,"title":["Tremblements et mouvements anormaux aigus d\u2019origine m\u00e9dicamenteuse"],"prefix":"10.1016","volume":"59","author":[{"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2004020_bb2005","first-page":"425","article-title":"Mouvements anormaux d\u2019origine m\u00e9dicamenteuse : l\u2019exp\u00e9rience d\u2019un centre de pharmacovigilance sur cinq ans","volume":"50","author":"Llau","year":"1995","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie:2004020_bb2010","series-title":"Rapport de neurologie pr\u00e9sent\u00e9 au Congr\u00e8s de Psychiatrie et de Neurologie de Langue Fran\u00e7aise, LXXXII\u00e8me session; 1984 juillet 2-7; Luxembourg","first-page":"51","article-title":"Les effets extrapyramidaux des psychotropes","author":"Pollak","year":"1984"},{"issue":"Suppl. 1","key":"10.2515\/therapie:2004020_bb2015","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1017\/S0317167100003309","article-title":"Antipsychotic drug-induced movement disorders","volume":"30","author":"Blanchet","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"10.2515\/therapie:2004020_bb2020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00002018-200326070-00003","article-title":"Benefits and risks of pharmacological treatments for essential tremor","volume":"26","author":"Lyons","year":"2003","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2004020_bb2025","first-page":"74","article-title":"Pharmacologie clinique des tremblements","volume":"9","author":"Montastruc","year":"1995","journal-title":"Lettre Pharmacol"},{"key":"10.2515\/therapie:2004020_bb2030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00002826-199506000-00001","article-title":"Tardive syndromes and other drug-induced movement disorders","volume":"18","author":"Jankovic","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2004020_bb2035","first-page":"394","volume":"1","author":"Lang","year":"1992"},{"key":"10.2515\/therapie:2004020_bb2040","first-page":"164","article-title":"Syndrome malin des neuroleptiques et syndrome s\u00e9rotoninergique : diagnostics positifs et \u00e9tiologies m\u00e9dicamenteuses","volume":"14","author":"Montastruc","year":"2000","journal-title":"Lettre Pharmacol"},{"key":"10.2515\/therapie:2004020_bb2045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00002018-200326070-00003","article-title":"Benefits and risks of pharmacological treatments for essential tremor","volume":"26","author":"Lyons","year":"2003","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2004020_bb2050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00002018-199716030-00004","article-title":"Drug-induced movement disorders","volume":"16","author":"Jimenez-Jimenez","year":"1997","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2004020_bb2055","first-page":"879","volume":"1","author":"Davies","year":"1991"},{"key":"10.2515\/therapie:2004020_bb2060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00002826-200205000-00004","article-title":"Drug-induced-movement disorders","volume":"25","author":"Rodnitzky","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2004020_bb2065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0301-0082(90)90009-6","article-title":"Drug-induced neurological disorders","volume":"34","author":"Dickey","year":"1990","journal-title":"Prog Neurobiol"},{"issue":"Suppl. 1","key":"10.2515\/therapie:2004020_bb2070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00023210-199600051-00005","article-title":"Management of acute antipsychotic-induced extrapyramidal syndromes","volume":"5","author":"Remington","year":"1996","journal-title":"CNS Drugs"},{"issue":"2","key":"10.2515\/therapie:2004020_bb2075","first-page":"CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.2515\/therapie:2004020_bb2080","first-page":"CD000459","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.2515\/therapie:2004020_bb2085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002018-199614060-00002","article-title":"Methods of managing levodopa-induced dyskinesias","volume":"14","author":"Giron","year":"1996","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2004020_bb2090","first-page":"485","article-title":"Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients","volume":"80","author":"Rascol","year":"1999","journal-title":"Adv Neurol"},{"issue":"4 Suppl. 1","key":"10.2515\/therapie:2004020_bb2095","first-page":"S179","article-title":"Medical treatment of levodopa-induced dyskinesias","volume":"47","author":"Rascol","year":"2000","journal-title":"Ann Neurol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T06:42:25Z","timestamp":1554273745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716301652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0040595716301652"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2004020","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}